Clinical Trials Logo

Clinical Trial Summary

The objective of this study is to determine the effect of low caffeine green tea extract containing 45% epigallocatechin gallate (EGCG) on fibroids and subsequent pregnancy and live births in women seeking fertility treatment. The population will consist of 50 women desirous of conceiving, ages ≥18 to ≤40 years (at time of consent), and known to have class 2-6 fibroids, according to the FIGO staging system.


Clinical Trial Description

The objective of this study is to conduct a randomized double-blinded clinical trial to determine the effect of low caffeine green tea extract on fibroids and subsequent pregnancy in women seeking fertility treatment. The investigators hypothesize that EGCG in low caffeine green tea extract will reduce the fibroid size, improve the quality of endometrium, and increase the likelihood of pregnancy. To test this hypothesis, the investigators propose a randomized placebo-controlled clinical trial to evaluate live birth outcomes for women with unexplained infertility who have uterine fibroids. Participants will be randomized to either oral low caffeine green tea extract (1650mg/day) vs. placebo along ovarian stimulation with clomiphene citrate and timed intrauterine insemination for up to 4 cycles. Endpoints Primary Endpoint: - Our primary endpoint is cumulative live birth rate. Secondary Endpoints: - The conception rate. - The miscarriage rate. - The change of fibroid volume, symptom severity score, and health-related quality-of-life score, from baseline to completion of treatment, and endometrial receptivity biomarkers. - Time to pregnancy This will be a randomized, multi-center, prospective, and double-blind clinical trial of low caffeine green tea extract versus placebo. Fifty (50) participants will be randomized via computer-generated randomization schedule to receive either: 1. low caffeine green tea extract (1650mg in 6 capsules) taken orally on a daily basis along with Clomiphene citrate-intrauterine insemination (CC-IUI) cycle, up to 4 cycles if no pregnancy is achieved. Participant will stop green tea if she becomes pregnant. or 2. matched (smell, taste, color, texture) placebo capsules taken orally on a daily basis along with CC-IUI cycle, up to 4 cycles if no pregnancy is achieved. Participant will stop placebo if she becomes pregnant. The randomization scheme will be on a 3:1 basis in favor of green tea extract, thus 37 participants will be assigned to the first arm (green tea extract) and 13 participants to the second arm (placebo). Clomiphene citrate will be taken for 5 days on Day 3 +/- 2 days of the participant's cycle. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05364008
Study type Interventional
Source Yale University
Contact Ayman Al-Hendy, MD, PhD
Phone 773-702-5954
Email aalhendy@BSD.Uchicago.edu
Status Recruiting
Phase Phase 3
Start date January 5, 2023
Completion date December 30, 2025

See also
  Status Clinical Trial Phase
Recruiting NCT04519593 - ABSOLUTELY: A Temporary Uterine Blood Supply Occlusion for Laparoscopic Myomectomy in Patients With UTErine LeiomYoma N/A
Recruiting NCT04935333 - Accuracy of the Preoperative Molecular Diagnosis of Uterine Tumors by Liquid Biopsy
Recruiting NCT05409872 - Effects of Vitamin D, Epigallocatechin Gallate, Vitamin B6, and D-Chiro-inositol Combination on Uterine Fibroids N/A
Completed NCT05517590 - Intravenous Tranexamic Acid and Intramyometrial Desmopressin Effect on Blood Loss During Laparoscopic Myomectomy. N/A
Active, not recruiting NCT05607602 - Are Uterine Fibroids Pro-thrombotic?
Terminated NCT04004884 - Liver Safety Assessment During Ulipristal Acetate Treatment for Uterine Fibroids (LISA)
Recruiting NCT04426760 - Fibroids and Infertility - a Study of the Significance of Removal of Fibroids With Regard to Endometrial Receptivity
Not yet recruiting NCT06442605 - Clinical Research on the Application of Single-channel Uterine Fibroid Morcellation System in Laparoscopic Myomectomy N/A
Recruiting NCT06143631 - Prescription of Letrozole for Uterine Myoma Phase 4
Recruiting NCT05518812 - Carboprost (Hemabate) for Fibroid Resection Early Phase 1
Recruiting NCT05500118 - Establishment of a Decision Aid Tool for Asymptomatic Small Leiomyoma and Analysis of Influencing Factors for Clinical Decision-making Using HIFU
Recruiting NCT03400826 - Effects of Simvastatin on Uterine Leiomyoma Size Phase 2